CTLA-4+ regulatory T cells are increased in cetuximab treated head and neck cancer patients, suppress NK cell cytotoxicity and correlate with poor prognosis (TUM2P.916)

Hyun-Bae Jie; Patrick Schuler; Steve Lee; Raghvendra Srivastava; Athanassios Argiris; Soldano Ferrone; Theresa Whiteside; Robert Ferris; Steve C. Lee

CTLA-4+ regulatory T cells are increased in cetuximab treated head and neck cancer patients, suppress NK cell cytotoxicity and correlate with poor prognosis (TUM2P.916)

Hyun-Bae Jie, Patrick Schuler, Steve Lee, Raghvendra Srivastava, Athanassios Argiris, Soldano Ferrone, Theresa Whiteside, Robert Ferris, Steve C. Lee

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Immunology
Volume	192
State	Published - May 1 2014

Disciplines

Immunology and Infectious Disease
Medicine and Health Sciences

OpenUrl availability

Full text

Cite this

@article{0cc61766b74d47e987b55e4aa1183162,

title = "CTLA-4+ regulatory T cells are increased in cetuximab treated head and neck cancer patients, suppress NK cell cytotoxicity and correlate with poor prognosis (TUM2P.916)",

author = "Hyun-Bae Jie and Patrick Schuler and Steve Lee and Raghvendra Srivastava and Athanassios Argiris and Soldano Ferrone and Theresa Whiteside and Robert Ferris and Lee, {Steve C.}",

note = "The EGFR-targeted antibody cetuximab is effective against head and neck cancer (HNSCC), but in only 15% to 20% of patients, and the variability and extent of cetuximab-mediated cellular immunity is not fully understood. We hypothesized that regulatory T cells (Treg) may exert a functional and clinical impact on antitumor immunity in cetuximab-treated individuals.",

year = "2014",

month = may,

day = "1",

language = "American English",

volume = "192",

journal = "Journal of Immunology",

}

TY - JOUR

T1 - CTLA-4+ regulatory T cells are increased in cetuximab treated head and neck cancer patients, suppress NK cell cytotoxicity and correlate with poor prognosis (TUM2P.916)

AU - Jie, Hyun-Bae

AU - Schuler, Patrick

AU - Lee, Steve

AU - Srivastava, Raghvendra

AU - Argiris, Athanassios

AU - Ferrone, Soldano

AU - Whiteside, Theresa

AU - Ferris, Robert

AU - Lee, Steve C.

N1 - The EGFR-targeted antibody cetuximab is effective against head and neck cancer (HNSCC), but in only 15% to 20% of patients, and the variability and extent of cetuximab-mediated cellular immunity is not fully understood. We hypothesized that regulatory T cells (Treg) may exert a functional and clinical impact on antitumor immunity in cetuximab-treated individuals.

PY - 2014/5/1

Y1 - 2014/5/1

UR - https://cancerres.aacrjournals.org/content/75/11/2200.long

M3 - Article

VL - 192

JO - Journal of Immunology

JF - Journal of Immunology

ER -

CTLA-4+ regulatory T cells are increased in cetuximab treated head and neck cancer patients, suppress NK cell cytotoxicity and correlate with poor prognosis (TUM2P.916)

Disciplines

OpenUrl availability

Other files and links

Cite this